CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肝细胞癌：局限期与晚期疾病的当前治疗策略
英文原题：Hepatocellular Carcinoma: Current Therapeutic Algorithm for Localized and Advanced Disease.
查看英文原题
Hepatocellular Carcinoma: Current Therapeutic Algorithm for Localized and Advanced Disease.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肝细胞癌（HCC）是不同病因肝硬化患者中最常见的原发性肝癌。近年来，对其分子机制认识加深且患者分期界定更精确，促进了新疗法开发并纳入治疗流程。深入了解 HCC 的分子驱动因素，有助于开发具有显著获益的靶向治疗。利用免疫检查点抑制剂、CAR-T 和 TCR-T 疗法靶向免疫逃逸的新策略也显示出令人鼓舞的结果。对于晚期疾病，近期因一线免疫治疗联合抗血管生成治疗的疗效，治疗算法已更新；目前也正在研究新药单药及联合方案。
展开英文摘要原文
Hepatocellular carcinoma (HCC) is the most common primary liver cancer in patients with liver cirrhosis of various etiologies. In recent years, there has been an advance in the knowledge of molecular mechanisms and a better staging definition of patients which has allowed the development of new therapies that have entered the therapeutic workup of these patients. Deep information on molecular drivers of HCC contributed to the development of targeted therapies with remarkable benefits.
The novel strategies of targeting immune evasion using immune checkpoint inhibitors and CAR-T and TCR-T therapeutics have also shown promising results. For advanced diseases, the therapeutic algorithm has been recently updated, thanks to the efficacy of combining immunotherapy and antiangiogenic therapy in the first-line setting, and new drugs, both as single-agents or combinations, are currently under investigation.
论文信息
- 作者
- Jose A、Bavetta MG、Martinelli E、Bronte F、Giunta EF、Manu KA
- 单位
- Department of Immunology, Amala Cancer Research Centre, Thrissur 680555, Kerala, India.India
- 文献类型
- 综述
- 期刊
- Journal of oncology2022
- 原文标识
- PubMed 36624801 · DOI 10.1155/2022/3817724